Joseph Williams, MD
Urology · Meridian, IDNPI 1194777060
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,439 of the $3,512 with a category attached, or 69.4%. 27 manufacturers reported payments, led by Telix Pharmaceuticals at 33.4% of the total. 2025 is the largest year on record at $1,673, 4.7 times the $353 reported in 2019.
Across 93 payments — averaging $37.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Telix Pharmaceuticals$1K
- Johnson & Johnson$291
- Neotract Inc.$279
- Dendreon Pharmaceuticals LLC$261
- AbbVie$185
- Astellas Pharma US Inc$174
- plus $1K from 21 others
Across 96 payments — averaging $3086.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$202K
- Janssen Research & Development, LLC$45K
- Sumitomo Pharma America, Inc.$26K
- Endo Pharmaceuticals Inc.$10K
- AbbVie$9K
- Urovant Sciences Inc$6K
What the payments were for
- Travel & lodging$82023%
- Food & beverage$2,43969%
- Education$2547%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Telix Pharmaceuticals | 5 | $1,173 |
| Johnson & Johnson | 15 | $291 |
| Neotract Inc. | 6 | $279 |
| Dendreon Pharmaceuticals LLC | 6 | $261 |
| AbbVie(2 entities) | 11 | $185 |
| Astellas Pharma US Inc | 2 | $174 |
| Coloplast | 3 | $166 |
| Merck | 8 | $157 |
| Urogen Pharma, Inc. | 5 | $134 |
| Accord Healthcare, Inc. | 7 | $131 |
| Bayer | 3 | $117 |
| Teleflex LLC | 2 | $74 |
| Ferring Pharmaceuticals Inc. | 3 | $47 |
| SN Holdings, LLC | 1 | $40 |
| Amgen | 2 | $34 |
| Olympus America Inc. | 2 | $32 |
| Medtronic | 1 | $26 |
| Innovation Technologies Inc | 1 | $24 |
| Travere Therapeutics, Inc. | 2 | $24 |
| Mirum Pharmaceuticals, Inc. | 1 | $23 |
| Bioprotect Medical, Inc. | 1 | $19 |
| Cardinal Health 414 LLC | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Rochester Medical Corporation | 1 | $18 |
| Immunitybio, Inc. | 1 | $18 |
| Endo USA, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,512 in reported general payments places this provider in the 55th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 92 | $53,412 |
| Finasteride | 1,558 | $19,611 |
| Testosterone | 42 | $18,195 |
| Tamsulosin Hcl | 1,248 | $13,494 |
| Dutasteride | 248 | $6,746 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $2,810 |
| Testosterone Cypionate | 57 | $2,701 |
| Potassium Citrate ErPotassium Citrate | 37 | $2,501 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 158 | $2,233 |
| Oxybutynin Chloride | 112 | $1,814 |
| Ciprofloxacin Hcl | 230 | $1,690 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $995 |
| Doxazosin Mesylate | 35 | $423 |
| Solifenacin Succinate | 15 | $402 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 47 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $174 | $53,41292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 55 urology providers in Idaho.
Other urology in Meridian
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
- Helen KuoMeridian$5K
- Brian AugeMeridian$5K
- Michael JacobsonMeridian$4K
- Kara SaperstonMeridian$4K
- Lisa ParrilloMeridian$3K
- Michael TaylorMeridian$3K
- Jared HeinerMeridian$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.